Synergistic enhancement of resistance to cisplatin in human bladder cancer cells by overexpression of mutant-type p53 and Bcl-2

Journal of Urology

Volumn 162, Issue 6, 1999, Pages 2176-2181

  Miyake, Hideaki ^a,b   Hara, Isao ^a   Yamanaka, Kazuki ^a   Arakawa, Soichi ^a   Kamidono, Sadao ^a  

^a KOBE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Bcl 2; Bladder cancer; Chemoresistance; Mutant type p53

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; CISPLATIN; COMPLEMENTARY DNA; DNA FRAGMENT; MUTANT PROTEIN; PROTEIN BCL 2; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; CANCER GROWTH; CANCER RESISTANCE; CELL VIABILITY; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DETERMINATION; DOSE TIME EFFECT RELATION; DRUG EFFICACY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

EID: 0032745655     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)68155-4     Document Type: Article

References (19)

1. Trasher, J. B. and Crawford, E. D.: Current management of invasive and metastatic transitional cell carcinoma of the bladder. J. Urol., 149: 957, 1993.
2. Chu, G.: Cellular response to cisplatin. J. Biol. Chem., 269: 787, 1994.
3. Miyake, H., Gohji, K., Hara, I., Eto, H., Yamanaka, K., Arakawa, S. and Kamidono, S.: Long-term results of neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for locally invasive transitional cell carcinoma of the urothelium. Int. J. Clin. Oncol., 4: 32, 1999.
4. Eliopoulos, A. G., Kerr, D. J., Herod, J., Hodgkins, L., Krajewski, S., Reed, J. C. and Young, L.: The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene, 11: 1217, 1995.
5. Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hostetter, R., Cleary K., Bringer, S. H., Collins, F. S., Weston, A., Modali, R., Harris, C. C. and Vogelstain, B.: Mutations in the p53 gene occur in diverse human tumor types. Nature, 342: 705, 1989.
6. Ogretmen, B. and Safa, A. R.: Expression of the mutated p53 tumor suppressor protein and its molecular and biochemical characterization in multidrug resistant MCF-7/Adr human breast cancer cells. Oncogene, 14: 499, 1997.
7. Reed, J. C.: Bcl-2 and the regulation of programmed cell death. J. Cell Biol., 124: 1, 1994.
8. Miyake, H., Hanada, N., Nakamura, H., Kagawa, S., Fujiwara, T., Hara, I., Eto, H., Gohji, K., Arakawa, S., Kamidono, S. and Saya, H.: Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene, 16: 933, 1998.
9. Kakehi, Y., Ozdemir, E., Habuchi, T., Yamabe, H., Hashimura, T., Katsura, Y. and Yoshida, O.: Absence of p53 Overexpression and favorable response to cisplatin-based neoadjuvant chemotherapy in urothelial carcinomas. Jpn. J. Cancer Res., 89: 214, 1998.
10. Miyake, H., Hara, I., Gohji, K., Yamanaka, K., Arakawa, S. and Kamidono, S.: Enhancement of chemosensitivity in human bladder cancer cells by adenoviral-mediated p53 gene transfer. Anticancer Res., 18: 3087, 1998.
11. Kawasaki, T., Tomita, Y., Bilim, V., Takeda, M., Takahashi, K. and Kumanishi, T.: Abrogation of apoptosis induced by DNA-damaging agents in human bladder cancer cell lines with p21/WAF1/CIP1 and/or p53 gene alterations. Int. J. Cancer, 68: 501, 1996.
12. Miyake, H., Yoshimura, K., Hara, I., Eto, H., Arakawa, S. and Kamidono, S.: Basic fibroblast growth factor regulates matrix metalloproteinases production and in vitro invasiveness in human bladder cancer cell lines. J. Urol., 157: 2351, 1997.
13. Miyake, H., Hara, I., Gohji, K., Arakawa, S. and Kamidono, S.: p53 modulation of Fas/Apo-1 mediated apoptosis in a human renal cell carcinoma cell line. Int. J. Oncol., 12: 469, 1998.
14. Miyake, H., Hara, I., Gohji, K., Yoshimura, K., Arakawa, S. and Kamidono, S.: Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line. Cancer Lett., 123: 121, 1998.
15. Esrig, D., Elmajian, D., Groshen, S., Freeman, J. A., Stein, J. P., Chen, S. C., Nichols, P. W., Skinner, D. G., Jones, P. A. and Cote, R. J.: Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med., 331: 1259, 1994.
16. King, E. D., Matteson, J., Jacobs, S. C. and Kyprianou, N.: Incidence of apoptosis, cell proliferation and bcl-2 expression in transitional cell carcinoma of the bladder: association with tumor progression. J. Urol., 155: 316, 1996.
17. Lowe, S. W., Ruley, H. E., Jacks, T. and Housman, D. E.: p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957, 1993.
18. Thomas, A., Rouby, S. E., Reed, J. C., Krajewski, S., Silber, R., Potmesil, M. and Newcomb, E. W.: Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene, 12: 1055, 1996.
19. Hawkins, S., Demers, G. W. and Galloway, D. A.: Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res., 56: 892, 1996.